Frasier syndrome, also known as familial juvenile hyperuricemic nephropathy (FJHN), is a rare genetic disorder characterized by increased uric acid levels in the blood (hyperuricaemia) and kidney dysfunction during childhood or adolescence. People with Frasier syndrome have mutations in the UMOD gene, which provides instructions for making uromodulin protein. Uromodulin plays an important role in the kidney’s ability to concentrate urine and regulate salt levels.
The global Frasier syndrome market is estimated to be valued at US$ 141.2 million in 2023 and is expected to exhibit a CAGR of 5.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The rising investments in research and development of novel treatment options for Frasier syndrome disease is expected to boost the market growth over the forecast period. For instance, in 2023, Reata Pharmaceuticals, Inc. revealed positive topline results from Part A of the Phase 3 Cardinal study of omaveloxolone in adults with Frasier syndrome. The study met its primary endpoint, with omaveloxolone demonstrating a statistically significant reduction in serum uric acid levels after four weeks of treatment compared to placebo. The increasing prevalence of Frasier syndrome globally is also anticipated to fuel the market growth. According to a study published in the American Journal of Kidney Diseases in 2023, the global prevalence of Frasier syndrome ranges from 1 in 50,000 to 1 in 100,000 individuals.
Frasier Syndrome market is dominated by the drug segment which accounts for around 60% of the total market share. The drug segment is further divided into antihistamines, decongestants and mast cell stabilizers. Among these, antihistamines dominate the segment with a share of over 45% as they provide effective treatment for sneezing, itching and other allergic symptoms associated with Frasier Syndrome. Decongestants hold the second largest share due to their efficacy in reducing nasal congestion.
Political: Governments across different countries are investing heavily in research related to rare diseases like Frasier Syndrome. Various regulations have also been introduced to promote orphan drug development.
Economic: Improvement in diagnosis and growing awareness about condition management are driving demand for effective therapeutic options. However, high costs associated with orphan drug development pose challenges.
Social: Patient support groups play a major role in creating awareness and advocating policy changes. Growing social media influence has also been instrumental in facilitating knowledge sharing.
Technological: Significant research is being focused on gene therapy and novel drug delivery mechanisms to address unmet needs. Advancements in fields of genetics and molecular biology have facilitated improved understanding of disease pathology.
The global Frasier Syndrome market is expected to witness high growth.
Regional Analysis: North America led by developed healthcare infrastructure and presence of key pharma companies.
Key players comprise key players operating in the Frasier Syndrome market are Denali Therapeutics Inc., Emmaus Life Sciences, Inc., ITF Pharma, Inc., BioMarin Pharmaceutical Inc. and Alexion Pharmaceuticals, Inc.
- Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it